Development of a simple HPLC–MS/MS method to simultaneously determine teriflunomide and its metabolite in human plasma and urine: Application to clinical pharmacokinetic study of teriflunomide sodium and leflunomide
- 7 January 2019
- journal article
- research article
- Published by Wiley in Biomedical Chromatography
- Vol. 33 (3) , e4420
Abstract
A simple high‐performance liquid chromatography coupled with tandem mass spectrometry method was developed and fully validated to simultaneously determine teriflunomide (TER) and its metabolite 4‐trifluoro‐methylaniline oxanilic acid (4‐TMOA) in human plasma and urine. Merely 50 μL plasma and 20 μL urine were employed in sample preparation using protein precipitation and direct dilution method, respectively. An Agilent Zorbax eclipse plus C18 column was selected to achieve rapid separation for TER and 4‐TMOA within 3 min. Electrospray ionization under multiple reaction monitoring was used to monitor the ion transitions for TER (m/z 269.0 → 159.9), 4‐TMOA (m/z 231.9 → 160.0), internal standard teriflunomide‐d4 (m/z 273.0 → 164.0) and 2‐amino‐4‐trifluoromethyl benzoic acid (m/z 203.8 → 120.1), operating in the negative ion mode. This method proved to have better accuracy and precision over concentration range of 10–5000 ng/mL in plasma as well as 10–10,000 ng/mL in urine. After a full validation, this method was successfully applied in a pharmacokinetic study of teriflunomide sodium and leflunomide in Chinese healthy volunteers.Keywords
Funding Information
- National Natural Science Foundation of China (81403013, 81403015)
This publication has 20 references indexed in Scilit:
- Clinical Pharmacokinetic Monitoring of Leflunomide in Renal Transplant Recipients with BK Virus Reactivation: A Review of the LiteratureClinical Pharmacokinetics, 2017
- Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of TeriflunomideTherapeutic Drug Monitoring, 2016
- The Efficacy and Safety of Leflunomide for the Treatment of Lupus Nephritis in Chinese Patients: Systematic Review and Meta-AnalysisPLOS ONE, 2015
- Pharmacokinetics and Bioequivalence Evaluation of Leflunomide Tablets in Korean Healthy VolunteersDrug Research, 2013
- Chromatographic separation and sensitive determination of teriflunomide, an active metabolite of leflunomide in human plasma by liquid chromatography-tandem mass spectrometryJournal of Chromatography B, 2010
- Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathwayAnnals of the Rheumatic Diseases, 2009
- Rapid determination of the active leflunomide metabolite A77 1726 in human plasma by high-performance liquid chromatographyJournal of Chromatography B, 2004
- Leflunomide Suppresses TNF-Induced Cellular Responses: Effects on NF-κB, Activator Protein-1, c-Jun N-Terminal Protein Kinase, and ApoptosisThe Journal of Immunology, 2000
- Mechanism of Action for Leflunomide in Rheumatoid ArthritisClinical Immunology, 1999
- Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritisClinical Therapeutics, 1999